NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(1) Feasibility Arrangement to test GreenLight Bioscience Inc s COVID-19 messenger RNA vaccine candidate as a shelf-stable dry powder formulation using TFF Pharmaceuticals Thin-Film Freezing technology. An easily reconstituted and shelf-stable dry powder formulation of messenger RNA COVID-19 vaccine could overcome the extreme low temperature cold chain requirements for current RNA vaccines. Eliminating extreme cold from the supply chain simplifies global distribution and opens vaccine availability to the large populations in regions and countries with limited refrigeration infrastructure. Should the study prove successful, the next phase may include non-needle administration of mRNA vaccines, including nasal spray and lung inhalation form.
NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Biotech Stock Picks That Delivered Triple-digit Gains - Is There More Room To Run?
NEW YORK CITY (dpa-AFX) - As 2020 draws to a close, it s time to take a look at the top performing healthcare stocks that we profiled this year. Of the 53 stocks to which our premium subscribers have been alerted, 18 stocks have posted triple-digit gains.
What are the catalysts driving these stocks? Is there more room to run? Let s walk you through the details.
1. DermTech Inc. (DMTK)
DermTech, a commercial-stage genomics company in dermatology, was trading around $11, when we alerted our premium subscribers to it on January 19, 2020. The stock touched a high of $27.42 in intraday trading yesterday and that represents a gain of 136% from our published price.